Client Login
An Overview of the Company
Meridian Lab stands as a specialized biopharmaceutical company dedicated to
pioneering advancement in cancer treatments through innovative NCE (New
Chemical Entity) and formulation enhancement. The company holds patents for
docetaxel and various formulations that utilize derivatives of beta-cyclodextrin.
Since 2012, Meridian Lab has been diligently engaged in progressive research
efforts achieved its major milestones in the product development and submissions in the last several years.
NDA: Meridian received the NDA approval in 2022 for ML141, its proprietary
formulation of Dcetaxel injectable. ML141 is known for its enhanced safety
compared to traditional Taxotere. This is cutting-edge solution eliminates the
use of Polysorbate 80 hence eliminated the hypersensitivity and the "Black Box"
warning on the side effects from Polysorbate 80.
Improved formulation: Meridian is developing Cabazitaxel Porlysorbate 80 free
formulation.
NCE: Meridian has initiated a proprietary new compound for a PARP+ATR dual
inhibitor as a targeted cancer therapy in various cancers.
Recent significant events and milestone research progress:
- In 2022, Meridian Lab Corporation's Docetaxel new drug application received approval from U.S. FDA.
- In 2022, Meridian completed the development of Cabazitaxel Polysorbate 80 free new formulation.
- In 2023, Meridian Lab initiated a new drug development project for a PARP+ATR dual inhibitor targeting prostate cancer.
